These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 20439848

  • 1. Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response.
    Hesse D, Krakauer M, Lund H, Søndergaard HB, Langkilde A, Ryder LP, Sorensen PS, Sellebjerg F.
    Neurology; 2010 May 04; 74(18):1455-62. PubMed ID: 20439848
    [Abstract] [Full Text] [Related]

  • 2. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N, Sorensen PS, Bendtzen K, Flachs EM.
    Mult Scler; 2009 May 04; 15(5):601-5. PubMed ID: 19299439
    [Abstract] [Full Text] [Related]

  • 3. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
    Pozzilli C, Prosperini L, Sbardella E, De Giglio L, Onesti E, Tomassini V.
    Neurol Sci; 2005 Dec 04; 26 Suppl 4():S174-8. PubMed ID: 16388353
    [Abstract] [Full Text] [Related]

  • 4. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R, Xu J, Bennett D, Sandrock A, Goelz S, European Interferon Beta-1a IM Dose-Comparison Study Investigators.
    Neurology; 2005 Jul 12; 65(1):40-7. PubMed ID: 16009883
    [Abstract] [Full Text] [Related]

  • 5. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
    Hesse D, Sellebjerg F, Sorensen PS.
    Neurology; 2009 Aug 04; 73(5):372-7. PubMed ID: 19652141
    [Abstract] [Full Text] [Related]

  • 6. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
    Boz C, Oger J, Gibbs E, Grossberg SE, Neurologists of the UBC MS Clinic.
    Mult Scler; 2007 Nov 04; 13(9):1127-37. PubMed ID: 17967840
    [Abstract] [Full Text] [Related]

  • 7. Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis.
    van der Voort LF, Gilli F, Bertolotto A, Knol DL, Uitdehaag BM, Polman CH, Killestein J.
    Arch Neurol; 2010 Apr 04; 67(4):402-7. PubMed ID: 20142519
    [Abstract] [Full Text] [Related]

  • 8. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial.
    Goodin DS, Hartung HP, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Kappos L, Bogumil T, Knappertz V, Sandbrink R, Beckmann K, White R, Petkau J, Pohl C, BEYOND Study Group.
    Mult Scler; 2012 Feb 04; 18(2):181-95. PubMed ID: 21952094
    [Abstract] [Full Text] [Related]

  • 9. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X.
    Mult Scler; 2008 May 04; 14(4):479-84. PubMed ID: 18562504
    [Abstract] [Full Text] [Related]

  • 10. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
    Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
    [Abstract] [Full Text] [Related]

  • 11. The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis.
    Namaka M, Pollitt-Smith M, Gupta A, Klowak M, Vasconcelos M, Turcotte D, Gong Y, Melanson M.
    Curr Med Res Opin; 2006 Feb 26; 22(2):223-39. PubMed ID: 16466595
    [Abstract] [Full Text] [Related]

  • 12. Measures in the first year of therapy predict the response to interferon beta in MS.
    Río J, Castilló J, Rovira A, Tintoré M, Sastre-Garriga J, Horga A, Nos C, Comabella M, Aymerich X, Montalbán X.
    Mult Scler; 2009 Jul 26; 15(7):848-53. PubMed ID: 19542263
    [Abstract] [Full Text] [Related]

  • 13. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
    Hegen H, Millonig A, Bertolotto A, Comabella M, Giovanonni G, Guger M, Hoelzl M, Khalil M, Killestein J, Lindberg R, Malucchi S, Mehling M, Montalban X, Polman CH, Rudzki D, Schautzer F, Sellebjerg F, Sørensen PS, Deisenhammer F.
    Mult Scler; 2014 Apr 26; 20(5):577-87. PubMed ID: 24009164
    [Abstract] [Full Text] [Related]

  • 14. Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production.
    Hedegaard CJ, Sellebjerg F, Krakauer M, Hesse D, Bendtzen K, Nielsen CH.
    Mult Scler; 2011 May 26; 17(5):567-77. PubMed ID: 21177756
    [Abstract] [Full Text] [Related]

  • 15. Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis.
    Gavasso S, Gjertsen B, Anderssen E, Myhr K, Vedeler C.
    Mult Scler; 2012 Aug 26; 18(8):1116-24. PubMed ID: 22287540
    [Abstract] [Full Text] [Related]

  • 16. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
    Perini P, Calabrese M, Biasi G, Gallo P.
    J Neurol; 2004 Mar 26; 251(3):305-9. PubMed ID: 15015010
    [Abstract] [Full Text] [Related]

  • 17. Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?
    Sorensen PS, Koch-Henriksen N, Bendtzen K.
    Mult Scler; 2007 Jun 26; 13(5):616-21. PubMed ID: 17548440
    [Abstract] [Full Text] [Related]

  • 18. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
    Pachner AR, Cadavid D, Wolansky L, Skurnick J.
    Neurology; 2009 Nov 03; 73(18):1485-92. PubMed ID: 19884576
    [Abstract] [Full Text] [Related]

  • 19. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun 03; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 20. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.
    Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Morra VB, Lo Fermo S, Picconi O, Tola MR, Trojano M, COGIMUS Study Group.
    Mult Scler; 2010 Jan 03; 16(1):68-77. PubMed ID: 19995846
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.